Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HSP-130 vs Neulasta PK/PD study in healthy volunteers
NCT02629289Phase 1Completed
- Sponsor
- Pfizer
- Start
- Aug 2015
- Primary completion
- Jun 2016
- Modality
- PEGylated Peptides, Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of pegfilgrastim-apgf in neutropenia (3 arms), sponsored by Pfizer. Primary endpoints: Area under the effect versus time curve for absolute neutrophil count and Maximum observed value for absolute neutrophil count. Started Aug 2015; status: completed.
02
Drugs
pegfilgrastim-apgf
03
Conditions
neutropenia
Beyond the preview
Go deeper on NCT02629289.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02629289.